This study was designed to evaluate the efficacy of therapeutic intensification with autologous stem cell transplantation (ASCT) for mantle cell lymphomas (MCL) in terms of response rate, duration of response, and event-free and overall survivals. Twenty-four patients with confirmed MCL responding to chemotherapy received a high-dose chemo-radiotherapy regimen followed by ASCT. Transplantation was performed during first-line therapy in nine cases, second-line in 13 cases and third-line in two cases. The source of hematopoietic stem cells was peripheral blood for 19 cases. At the time of ASCT, eight patients were in complete remission (33%). Seventeen of the 24 cases received an intensified regimen with TBI and seven received the BEAM or the BEAC regimen. After transplantation, 19 patients were in CR (79%). Nine of these were alive in continued CR at a median follow-up of 34 months, while seven relapsed at a median of 18 months. One patient died from Pneumocystis carinii interstitial pneumonitis and five patients developed secondary malignancies. With a median follow-up after transplantation of 34 months, the 3-year event-free survival was 55% and the 3-year overall survival was 68%. These results indicate that therapeutic intensification with ASCT might be an effective treatment for mantle cell lymphomas. cycline-based chemotherapy of about 60%, the duration of response is extremely short for most patients and the prognosis remains poor with a median survival of less than 3 years. New approaches are therefore warranted to improve this dismal outcome. Chemotherapeutic agents such as fludarabine 11 and 2-chlorodeoxyadenosine 12 have been tested, with no improvement of survival. Hyper-CVAD and high-dose methotrexate/cytarabine appears to be a promising regimen with a response rate of 93% and 38% complete responses.
cycline-based chemotherapy of about 60%, the duration of response is extremely short for most patients and the prognosis remains poor with a median survival of less than 3 years. New approaches are therefore warranted to improve this dismal outcome.
Chemotherapeutic agents such as fludarabine 11 and 2-chlorodeoxyadenosine 12 have been tested, with no improvement of survival. Hyper-CVAD and high-dose methotrexate/cytarabine appears to be a promising regimen with a response rate of 93% and 38% complete responses. 13 Immunotherapy using monoclonal anti-CD20 antibody, rituximab, has been associated with a 33% response rate. 14 Similarly, a slight prolongation of the median duration of response with interferon alpha has been reported in a few series, with no impact on overall survival. 5, 15, 16 Several non-randomized studies of myeloablative chemo-and/or radiotherapy regimens have recently been published with controversial views concerning their impact on progressionfree and overall survivals. 13, [17] [18] [19] [20] [21] [22] [23] [24] The objectives of this report were (1) to evaluate, in 24 confirmed cases of MCL, the efficacy of therapeutic intensification on response rate, duration of response, event-free and overall survival; and (2) to discuss the true impact of autologous stem cell transplantation for mantle cell lymphomas based on a review of the literature.
Patients and methods

Patient population
Thirty-four patients undergoing autologous stem cell transplantation (ASCT) between 1994 and 1997 in seven Hematology Departments and diagnosed as having mantle cell lymphoma were included in this study.
All slides were reviewed by a hematological pathologist (NB) and the diagnosis of MCL was based on a combination of morphologic, immunophenotypic and cytogenetic criteria. The histologic review included analysis of the morphological appearance of cells and the architectural pattern. Immunohistochemical analysis, performed on histologic material and/or peripheral blood cells or bone marrow aspirates, used several monoclonal antibodies (CD3, CD5, CD10, CD19, CD20, CD23, and heavy and light chain Bone Marrow Transplantation immunoglobulins). Cytogenetic abnormalities, detected with a RHG banding technique, 25 were described according to the International System for Human Cytogenetic Nomenclature. 26 The diagnosis of MCL was confirmed (1) in the presence of a Bcl-2 positive nodular proliferation with residual Bcl-2 negative germinal centers of small-to medium-size cells with irregular nuclei (cleaved cells); and (2) in the case of diffuse pattern and/or small round or large blastoid cells, by CD5 positivity and/or the presence of typical t(11;14)(q13;q32).
Staging work-up included clinical examination, blood count, liver function and serum lactate dehydrogenase determination, chest X-ray, CT scans and bone marrow aspirate or biopsy. Fiberoptic gastroscopy was performed when indicated. The Ann Arbor classification was used for staging. Follow-up restaging was performed before and after transplantation.
Autologous stem cell transplantation was performed during first-line therapy in nine cases, second-line therapy in 13 cases and third-line therapy in two cases. Median time between diagnosis and transplantation was 6 months for patients transplanted during first-line therapy (range, 3-30 months) and 32 months for the remaining cases (range, 8-119 months). Before stem cell mobilization, patients were treated with several lines of chemotherapy: 13 patients received an anthracycline-based regimen (9 CHOP or CHOP-like and 4 ACVBP) (see below), nine cases received salvage chemotherapy (DHAP, ESHAP, IVAM, VIM3A-raC and MAMI) and three patients were treated with fludarabine alone. At the time of ASCT, eight patients were in CR (33%), 15 were in PR and one had a minor response.
Collection and processing of hematopoietic stem cells
Hematopoietic stem cells were obtained from bone marrow in five patients and peripheral blood in 19 cases. For three patients, bone marrow transplantation was performed after insufficient collection of peripheral blood stem cells. Blood stem cells were collected after recovery from conventional chemotherapy plus G-CSF (granulocyte colony-stimulating factor) (5 g/kg/day). Several chemotherapy regimens were used for mobilization: cyclophosphamide plus etoposide in 13 cases, cyclophosphamide alone in two, mBEAM-ACVBP-IVAM, and MAMI (see below) regimen in one case each.
The median CD34 ϩ hematopoietic stem cell count was 5 ϫ 10 6 /kg (range, 1.89-17.1 ϫ 10 6 /kg). In two cases, transplantation was performed with selection of CD34-positive peripheral blood stem cells.
Conditioning regimen and post-transplant measures
Among the 24 patients studied, 13 received the TEC regimen (total-body irradiation, TBI, 8 to 12 Gy; cyclophosphamide 4500 mg/m 2 ; etoposide 450 mg/m 2 ), four received a combination of cyclophosphamide (120 mg/kg) and TBI (12 Gy), and seven received the BEAM or BEAC regimen.
Following infusion of hematopoietic stem cells, all patients were nursed in individual rooms using protective isolation. Febrile episodes were investigated and treated with broad spectrum antibiotics. Transfusion support with irradiated blood products was carried out with a hemoglobin Ͻ8 g/dl and to maintain a platelet count above 20 ϫ 10 9 /l.
Study definitions and statistics
Complete response was defined as the disappearance of all clinical evidence of lymphoma; partial response was defined as greater than 50% decrease in the sum of the products of the diameter of all measurable lesions. Response to therapy was assessed a minimum of 4 weeks after completion of treatment. Duration of response was calculated from the date of transplantation until relapse or death. Event-free survival (EFS) was calculated from the date of stem cell infusion (day 0) to the date of relapse or death, or to the date last known. Overall survival (OS) was calculated from the date of transplantation to the date a patient was last known to be alive or to the date of death. Survival curves were estimated by the Kaplan-Meier method. Univariate analysis of prognostic factors was performed using the 2 test.
Chemotherapy regimens
CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; ACVBP, cyclophosphamide, doxorubicin, vindesine, bleomycin and prednisone; DHAP, dexamethasone, aracytine and cisplatin; ESHAP, etoposide, dexamethasone, aracytine and cisplatin; IVAM and VIM3AraC, ifosfamide, etoposide, aracytine and methotrexate; MAMI, ifosfamide, aracytine, methyl-gag and amsacrine; mBEAM, BCNU, etoposide, aracytine, melphalan and dexamethasone; BEAM, BCNU, etoposide, aracytine and melphalan; BEAC, BCNU, etoposide, aracytine and cyclophosphamide.
Results
Histologic and cytogenetic data
Among the 34 cases reviewed, 24 were considered to have MCL. The 10 NHL excluded were follicular center lymphoma (n ϭ 2), MALT lymphoma (n ϭ 1), diffuse large cell lymphoma (n ϭ 2) and five because of insufficient material for adequate classification. The architectural pattern was nodular in nine cases, nodular and diffuse in one case and diffuse in 14 cases. The cells had a typical appearance (small cleaved cells) in 22 cases. The two remaining cases had large blastoid cells and typical immunophenotype CD5 ϩ , CD10 Ϫ and CD23 Ϫ . Cytogenetic analysis was performed in 13 cases and a t(11;14)(q13;q32) was found in nine cases with other abnormalities in eight cases. Details concerning morphology, immunophenotyping and cytogenetic data are shown in Table 1 .
Patient characteristics
At the time of diagnosing lymphoma, the median patient age was 47 years (range, 39-60 years). 33% of patients had B-symptoms. Nodal involvement was present in all cases Table 2 .
Treatment course
After transplantation, 19 patients were in CR (79%) and five were in PR. Among the patients in CR, nine patients (47%) were alive and in continued complete remission after transplantation for a median of 34 months (range, 20-51 months) and seven patients relapsed after a median of 18 months (range, 3-44 months). The three remaining cases, still in complete remission, died of lung infection, acute myeloid leukemia and stomach cancer, 4, 15 and 30 months after transplantation, respectively. With a median follow-up of 34 months, the 3-year eventfree survival was 55% (95% confidence interval, 34-75%) and the 3-year overall survival was 68% (95% confidence interval, 46-88%) (Figures 1 and 2, respectively) . All data concerning treatment outcome are described in Table 3 . Among the two patients transplanted with CD34-positive peripheral blood stem cells, one died from acute myeloid Three patients died from secondary malignancies: two of acute myeloid leukemia diagnosed 15 and 30 months after ASCT and one of stomach cancer diagnosed 30 months after ASCT. Two other patients developed a secondary malignancy: bladder cancer and head and neck cancer, 8 and 40 months after transplantation, respectively. The median age of these five patients was 45 years (range, 42-48 years); three were treated with fludarabine and four received total body irradiation. Moreover, ASCT was performed as second-or third-line therapy for four patients.
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Univariate analysis
The prognostic impact of various pathological (nodular or nodular and diffuse vs diffuse architectural pattern) and clinical parameters (B-symptoms, generalized adenopathy (Ͼ2 areas), spleen, Waldeyer's ring, gastrointestinal or bone marrow involvement, leukemic phase, number of extranodal sites greater than one, elevated serum LDH level and IPI score 0-1-2 vs 3-4-5) was analyzed with respect to complete response, event-free and overall survivals. None of these criteria correlated with failure to achieve CR, poor EFS and OS. Moreover, TBI included in the conditioning regimen did not influence the post-transplantation response rate, EFS or OS. Similarly, we did not observe any impact of number of lines of therapy before intensification ( Figure 3) .
Discussion
High-dose chemotherapy and/or radiotherapy regimens with autologous stem cell transplantation have been studied in several varieties of NHL, including newly diagnosed and relapsed low-or high-grade lymphomas. The poor prognosis of mantle cell lymphomas requires that such a therapeutic approach be evaluated in terms of continued complete remission and overall survival. Our series is one of the very few to assess the outcome of transplanted patients with confirmed MCL, with a sufficiently long follow-up.
Various series of patients with mantle cell lymphoma treated with myeloablative chemo-and/or radiotherapy regimens have been reported in the literature (the most extensive publications are described in Table 4 ). Very few studies, 13, 19, 20, 22 have confirmed that the diagnosis of MCL was based on up-to-date published criteria of the REAL or WHO classifications. Histopathological review therefore confers a more realistic value on our work in terms of defining the efficacy of therapeutic intensification for mantle cell lymphomas.
Of the 24 patients eligible for assessment, with 60% receiving second-or third-line therapy, we observed a high response rate with 79% complete remissions. Among these 19 patients, nine were in continued CR with a median follow-up of almost 3 years. Apart from the report of Ketterer et al, 19 all published series have shown a high complete response rate after transplantation. This result demonstrates the possibility of effecting complete resolutions of the disease with therapeutic intensification. However, it must be noted that the evaluation performed after ASCT did not include molecular analysis of blood or bone marrow cells.
The early toxicity of such treatment remained acceptable, Table 3 Treatment outcome date n ϭ number of patients; OS ϭ overall survival; EFS ϭ event-free survival; DFS ϭ disease-free survival; FFS ϭ failure-free survival; PFS ϭ progressionfree survival; OSx, x-year overall survival. with only one death occurring due to Pneumocystis carinii interstitial pneumonitis. In contrast, five patients (21%) developed secondary malignancies 8 to 40 months after ASCT. This incidence of secondary malignancies is higher than that generally reported, 27, 28 but suggests that high-dose chemo-and/or radiotherapy regimen has a carcinogenic potential which must not be overlooked. Given the limited number of patients, it was not possible to identify predictive factors for secondary malignancies.
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Given the natural history of mantle cell lymphoma and its median survival of 3 years, our results are confirmed by our long median follow-up of 35 months after transplantation; in contrast, in all other series, the median follow-up varied between 8 and 30 months. With a 3-year event-free survival of 55% and a 3-year overall survival of 68%, we note the efficacy of such a myeloablative regimen for untreated or relapsed MCL. We and others have observed several patients with lasting first or second complete remissions. 13, 18, 20, 21, 23, 24 Furthermore, of the 28 untreated patients reported by Freedman et al, 22 nine remain in complete response after ASCT with a median follow-up of 24 months. Lastly, because of the small numbers of patients, it was not possible to define prognostic factors influencing complete response rates and event-free and overall survivals, and particularly, the impact of type of conditioning and number of lines of therapy before transplantation.
In conclusion, high-dose chemo-and/or radiotherapy with ASCT appears to be an effective approach in improving the prognosis of mantle cell lymphomas. The high response rate, and particularly the high proportion of complete responses, suggests that therapeutic intensification of mantle cell lymphoma could be extensively used to reduce tumor mass permitting use of immunotherapy for residual disease. Further multicenter studies are therefore warranted to evaluate the impact of autologous stem cell transplantation on outcome of MCL as first-line therapy.
